Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Agents acting on renin-angiotensin system: the impact of generics and price trends in Croatia (CROSBI ID 625717)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Kučan, Marta ; Mršić-Pelčić, Jasenka ; Mance, Diana ; Vitezić, Dinko Agents acting on renin-angiotensin system: the impact of generics and price trends in Croatia // Clinical therapeutics. 2015. str. e71-e71 doi: 10.1016/j.clinthera.2015.05.214

Podaci o odgovornosti

Kučan, Marta ; Mršić-Pelčić, Jasenka ; Mance, Diana ; Vitezić, Dinko

engleski

Agents acting on renin-angiotensin system: the impact of generics and price trends in Croatia

Adequate cardiovascular therapy that includes usage of Agents acting on renin-angiotensin system (RAS), (ATC, C09) results in the reduction of cardiovascular morbidity and mortality. It is important to establish measures for higher usage of cheaper generics which will lead to the reduction of the healthcare costs. The aim of our study was to identify and analyse changes in the usage of original and generics drugs in RAS subgroup agents in Croatia from 2000-2013 and to identify the rate of the generic drugs usage as well as the average price for 1 DDD. Data on the consumption have been obtained from the database IMS (International Medical Statistics) for Croatia. According to the World Health Organization Collaborating Centre for Drugs Statistics Methodology annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while drug costs data are presented in Euro per DDD. The usage of original drugs increased from 5.86 DDD/1000/day to 63.56 during the investigated period and generics increased from 52.70 to 136.32. Consumption share of generics decreased from 90% in 2000 to 56% in 2006, and then we had constant increase to 68% in 2013. Average price of 1 DDD for both original and generic drugs in C09 subgroup decreased in total from 0.31 EUR/DDD in 2000 to 0.16 EUR/DDD in 2013, which is decrease of 48.91% (39.42% for originals, and 55.57% for generics). The national healthcare policy promoting generics resulted in their increase of usage up to 2013, but due to the introduction of new INNs in subgroup (Angiotensin II antagonists, plain and combinations) it was less obvious then expected. The price trend showed price decrease in originals and generics as a result of price reduction policy introduced by Croatian National Insurance Company, but it is necessary to introduce new measures for further generic promotion.

cardiovascular therapy ; renin-angiotensin system ; generics ; price trends

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

e71-e71.

2015.

nije evidentirano

objavljeno

10.1016/j.clinthera.2015.05.214

Podaci o matičnoj publikaciji

Clinical therapeutics

0149-2918

Podaci o skupu

12th Congress of the European Association for Clinical Pharmacology and Therapeutics

poster

27.06.2015-30.06.2015

Madrid, Španjolska

Povezanost rada

Kliničke medicinske znanosti

Poveznice